natera™ | Prospera™
Transplant assessment

NEW
Available now



Covered by Medicare

Prospera™ precision—
for critical decisions
when the stakes are high

Introducing Prospera

Prospera is powered by highly optimized, proprietary cell-free DNA (cfDNA) technology. As part of your tool kit, Prospera assesses all types of kidney transplant rejection[2] with great precision.[1,3]

- Simpler and less invasive than biopsy
- More sensitive and specific than current assessment tools across all types of rejection[2,4,5]
- Up to 5x less variability than first-generation donor-derived cell-free DNA technology[1,3]
- Covered by Medicare for all kidney transplant recipients

Powering clear and confident decisions

Developed by Natera with our trusted legacy in cfDNA, Prospera is optimized to be the most precise cfDNA tool for early, clinically meaningful rejection assessment.[1,3]

HOW PROSPERA WORKS



PERSONALIZED ASSESSMENT



Experts in cell-free DNA. Optimized for transplantation.

To improve the management of organ transplantation, cancer, and reproductive health, Natera is harnessing the power of cfDNA from a single blood sample and a methodology that uses single-nucleotide polymorphisms (SNPs) for non-invasive testing.

Refined workflow. Only from Natera.

Natera's core technology and finely tuned workflows cut through the noise to deliver superior clinical and analytical performance.[1,2]



~2M
cfDNA tests performed

>100
clinicians, PhD's, and scientists

90
countries worldwide

CAP
accredited

CLIA
certified

With all of the rapid advances taking place in cfDNA at Natera, our unwavering commitment to improving the health and care of your patients remains constant.

Unparalleled precision. Optimized by Prospera.

1 Highly optimized to significantly reduce variability

Based on analytical validation data, Prospera exhibited **up to 5x less variability** in results.[1,3]

Patient Test Summary Example*



*Depicted ranges are ±1 standard deviation from actual dd-cfDNA level based on coefficient of variations[1,3]

2 Now—catch ALL rejection types with a single blood draw

Prospera's unique ability to identify T cell-mediated rejection gives a more comprehensive view of your patient's rejection status.[2,5]

Rejection Types	Prospera[2]	First-generation dd-cfDNA[6]
Antibody-mediated rejection (ABMR)	✓ Yes	✓ Yes
T cell-mediated rejection (TCMR) ≥ IA	✓ Yes	✗ No

Prospera is the first cfDNA assay to publish performance in surveillance situations, providing results that can enable physicians to manage patients with previously unsuspected rejection.[2]

3 Lower risk of missing active rejection

In the event of a result with dd-cfDNA level <1%, Prospera's likelihood of a patient not experiencing active rejection† outperforms existing options.[2,5]

Comparison of Negative Predictive Values (NPV) from published validation studies



Based upon 25% prevalence of active rejection[2,5]

4 Ultra-sensitive for more accurate classification

When comparing published clinical validation studies, Prospera demonstrated better performance in correctly classifying patients with active rejection—including cell-mediated rejection.[2,5] Other tests may incorrectly classify patients experiencing active rejection as normal (up to 1 out of 2 cases).[5]

Of 100 active rejection cases, the number of patients who would be missed, with dd-cfDNA <1%‡



† ‡Using a 1% dd-cfDNA threshold

Patients first. Partners always.



Pledging ongoing support and resources

Natera offers outstanding support for your patients

- Medicare coverage for Prospera to renal transplant patients
- Proactive billing outreach and price transparency
- Convenient complimentary phlebotomy services—either on-site, via mobile phlebotomy or at any of the >1,000 patient services blood draw centers

We also back you and other physicians with resources

- Direct support from clinical staff to discuss your patients' results
- Prospera Provider Portal plus EMR integration options so you can easily order, track and receive patients' reports

Our initiatives are tailored for your transplant nurses and coordinators

- ProsperaLink Program of dedicated Natera nurses and patient care coordinators
- Dedicated operations team to ensure ease of integration into your current patient care workflow

Natera welcomes all insurances. Prospera is covered by Medicare for assessing potential kidney transplant rejection. The goal of Natera's billing department is to make the process transparent and easy for our patients. In the rare event your patient has financial responsibility for Prospera, Natera offers flexible financial assistance programs and will work closely with your patient to ensure there is no hardship on them or their family.

In all cases, the Natera team is here to help you, your staff, and your patients with any billing or reimbursement questions and needs at **+1 650.273.4468**.

Prospera precision. Setting a new standard through research.

Best-in-class transplant care depends on best-in-class assessment. Prospera is the most advanced cfDNA solution for assessing transplant rejection—reinforced by ongoing research efforts:

Sigdel et al
Clinical Validation
Published 2019

- Conducted with the University of California, San Francisco
- Largest biopsy-matched study conducted in renal transplantation assessing the use of cfDNA
- First to publish performance of cfDNA testing in subclinical, surveillance setting

ProActive Registry Study
Now enrolling

- Largest clinical utility study evaluating cfDNA; includes more than 3,000 kidney transplant patients studied over three years
- Long-term assessment of high-risk recipients for up to five years post-transplantation
- Personalized transplant management protocols using cfDNA data

Research with MMDx
(Molecular Microscope Diagnostic System)
Now enrolling

- Global, prospective multicenter study under the leadership of Dr. Philip Halloran
- 300 patients to be comprehensively evaluated with clinical information, cfDNA measures, biopsies, molecular microscope, evaluations, and donor-specific antibodies (DSA)
- Integrated data analysis to better inform non-invasive and interventional management in kidney transplantation

REFERENCES

1 Altug Y, Liang N, Ram R, et al. Analytical validation of a single-nucleotide polymorphism-based donor-derived cell-free DNA assay for detecting rejection in kidney transplant patients [published online February 19, 2019]. *Transplantation*. 2019. doi: 10.1097/TP.0000000000002665
2 Sigdel TK, Archila FA, Constantin T, et al. Optimizing detection of kidney transplant injury by assessment of donor-derived cell-free DNA via massively multiplex PCR. *J Clin Med*. 2018;8(1):pii E19.
3 Grskovic M, Hiller DJ, Eubank LA, et al. Validation of a clinical-grade assay to measure donor-derived cell-free DNA in solid organ transplant recipients. *J Mol Diagn*. 2016;18(6):890-902.
4 Bromberg JS, Brennan DC, Poggio E, et al. Biological variation of donor-derived cell-free DNA in renal transplant recipients: clinical implications. *J Appl Lab Med*. 2017;2(3):309-321.
5 Bloom RD, Bromberg JS, Poggio ED, et al. Cell-free DNA and active rejection in kidney allografts. *J Am Soc Nephrol*. 2017;28(7):2221-2232. doi: 10.1681/ASN.2016091034.
6 Huang E, Sethi S, Peng A, et al. Early clinical experience using donor-derived cell-free DNA to detect rejection in kidney transplant recipients. *Am J Transplant*. 2019; 19:1663-1670.

201 Industrial Road, Suite 410, San Carlos, CA 94070 | Main +1 650.249.9090 | Fax +1 650.730.2272 | natera.com

natera™
Conceive. Deliver. Thrive.

Learn more about Prospera:
Call us +1 650.273.4468
Visit us natera.com/prospera